ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FUM Futura Medical Plc

35.50
-1.00 (-2.74%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -2.74% 35.50 35.40 35.60 35.80 35.30 35.80 218,444 16:35:04
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -18.25 106.45M

Futura Medical PLC Remuneration of Non-Executive Directors and TVR (8957M)

11/01/2019 11:01am

UK Regulatory


Futura Medical (LSE:FUM)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Futura Medical Charts.

TIDMFUM

RNS Number : 8957M

Futura Medical PLC

11 January 2019

Remuneration of Non-Executive Directors and Total Voting Rights

11 January 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces the issue of 76,828 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2018 remuneration of its Non-Executive Directors.

In accordance with the terms of their service agreements, the Non-Executive Directors receive approximately 30 per cent of their remuneration in the form of Ordinary Shares. For 2018, these were issued at 25.10 pence per share, being the average closing mid-market price of the last 10 trading days of 2017 (as announced via RNS on 2 January 2018).

The 76,828 new ordinary shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued as follows:

 
 Director            Number of Ordinary Shares        Total number of ordinary shares   Percentage of the Company's 
                     issued for 2018 remuneration     held                              resulting issued share capital 
 John Clarke         57,250                           256,226                           0.13% 
 Jonathan Freeman    19,578                           90,621                            0.04% 
 

Application has been made to the London Stock Exchange and it is anticipated that trading of the new ordinary shares will commence on AIM at 8:00am on 16 January 2019.

Immediately following the above issue, the Company will have 204,660,267 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 204,660,267 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The shares element of the Non-Executive Directors' remuneration for 2019 will be awarded at 6.01 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2018. The Non-Executive Directors will receive these shares in January 2020.

Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

ENDS

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:

N+1 Singer

Aubrey Powell/ Ben Farrow (Corporate Finance)

Tom Salvesen/ Mia Gardner (Corporate Broking)

Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                            John Clarke 
     ------------------------------  ----------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status                 Director/ PDMR 
     ------------------------------  ----------------------------------- 
 b)   Initial notification            Initial notification 
       /Amendment 
     ------------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                            Futura Medical plc 
     ------------------------------  ----------------------------------- 
 b)   LEI                             21380053QLT46UNV2303 
     ------------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the 
       financial instrument,            Ordinary shares of 0.2p each 
       type of instrument 
                                        GB0033278473 
       Identification code 
     ------------------------------  ----------------------------------- 
 b)   Nature of the transaction       Issue of shares 
     ------------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)            Price(s)       Volume(s) 
                                         25.10 pence    57,250 
                                                       ---------- 
     ------------------------------  ----------------------------------- 
 d)   Aggregated information 
 
       - Aggregated volume 
                                        Not applicable 
       - Price 
     ------------------------------  ----------------------------------- 
 e)   Date of the transaction         11 January 2019 
     ------------------------------  ----------------------------------- 
 f)   Place of the transaction        Outside of trading venue 
     ------------------------------  ----------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                            Jonathan Freeman 
     ------------------------------  ----------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status                 Director/ PDMR 
     ------------------------------  ----------------------------------- 
 b)   Initial notification            Initial notification 
       /Amendment 
     ------------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                            Futura Medical plc 
     ------------------------------  ----------------------------------- 
 b)   LEI                             21380053QLT46UNV2303 
     ------------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the 
       financial instrument,            Ordinary shares of 0.2p each 
       type of instrument 
                                        GB0033278473 
       Identification code 
     ------------------------------  ----------------------------------- 
 b)   Nature of the transaction       Issue of shares 
     ------------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)            Price(s)       Volume(s) 
                                         25.10 pence    19,578 
                                                       ---------- 
     ------------------------------  ----------------------------------- 
 d)   Aggregated information 
 
       - Aggregated volume 
                                        Not applicable 
       - Price 
     ------------------------------  ----------------------------------- 
 e)   Date of the transaction         11 January 2019 
     ------------------------------  ----------------------------------- 
 f)   Place of the transaction        Outside of trading venue 
     ------------------------------  ----------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHKMGMMGMRGLZM

(END) Dow Jones Newswires

January 11, 2019 06:01 ET (11:01 GMT)

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart

Your Recent History

Delayed Upgrade Clock